Almost 60% of patients met the primary endpoint of progression-free survival (PFS) at 6 months with the CDK4/6 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results